ALGS Stock Price, Aligos Therapeutics Inc Quote, Chart

Market Summary

USD0.73+0.08

Delayedas of 17 May 2024, 11:02 am

12.31%

ALGS Stock Price

View Fullscreen

ALGS RSI Chart

ALGS Valuation

Market Cap

49.2M

Price/Earnings (Trailing)

-0.49

Price/Sales (Trailing)

5.93

EV/EBITDA

-0.26

Price/Free Cashflow

-0.62

ALGS Price/Sales (Trailing)

ALGS Profitability

EBT Margin

-1190.45%

Return on Equity

-166.54%

Return on Assets

-77.86%

Free Cashflow Yield

-161.38%

ALGS Fundamentals

ALGS Revenue

Revenue (TTM)

8.3M

Rev. Growth (Yr)

-73.13%

Rev. Growth (Qtr)

-40.07%

ALGS Earnings

Earnings (TTM)

-99.6M

Earnings Growth (Yr)

-51.88%

Earnings Growth (Qtr)

-24.99%

Breaking Down ALGS Revenue

52 Week Range

0.661.22

(Low)(High)

Last 7 days

-16.7%

Last 30 days

-21.7%

Trailing 12 Months

-45.4%

How does ALGS drawdown profile look like?

ALGS Financial Health

Current Ratio

6.25

ALGS Investor Care

Shares Dilution (1Y)

76.22%

Diluted EPS (TTM)

-1.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.3M	0	0	0
2023	13.9M	14.5M	12.6M	10.2M
2022	6.0M	8.2M	10.7M	13.9M
2021	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aligos Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 25, 2023	nuechterlein carole	bought	6,004,150	0.7568	7,933,600	-
Oct 25, 2023	scopa james paul	acquired	138,557	0.7568	183,083	-
Oct 25, 2023	blatt lawrence	acquired	461,858	0.7568	610,277	chief executive officer
Jun 11, 2021	woiwode thomas	acquired	-	-	18,102	-
Jun 11, 2021	woiwode thomas	acquired	-	-	2,226	-
Apr 26, 2021	woiwode thomas	acquired	-	-	18,105	-
Apr 26, 2021	woiwode thomas	acquired	-	-	2,226	-
Oct 20, 2020	woiwode thomas	bought	3,000,000	15.00	200,000	-
Oct 20, 2020	symons julian a.	acquired	-	-	18,517	see remarks
Oct 20, 2020	beigelman leonid	acquired	-	-	254,702	president

Which funds bought or sold ALGS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	EcoR1 Capital, LLC	unchanged	-	2,019,070	6,261,680	0.16%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-57.17	-4,573	7,862	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-9,787	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	285	89,388	108,448	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	656,142	2,034,870	0.03%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-24.65	162,942	1,617,000	0.17%
May 15, 2024	HarbourVest Partners LLC	unchanged	-	5,935	18,407	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	unchanged	-	5,886	18,252	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	new	-	2,415,220	2,415,220	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	new	-	490,000	490,000	0.04%

Are Funds Buying or Selling ALGS?

Are funds buying ALGS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALGS

No. of Funds

Unveiling Aligos Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	hhlr advisors, ltd.	8.2%	5,971,426	SC 13G/A
Feb 14, 2024	armistice capital, llc	9.99%	7,214,823	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.99%	7,264,147	SC 13G/A
Feb 14, 2024	alyeska investment group, l.p.	9.99%	7,176,767	SC 13G
Feb 14, 2024	baker bros. advisors lp	4.99%	3,664,013	SC 13G/A
Feb 14, 2024	tang capital partners lp	3.0%	2,189,847	SC 13G/A
Feb 08, 2024	versant venture capital vi, l.p.	1.9%	1,457,937	SC 13D/A
Nov 07, 2023	roche finance ltd	15.35%	11,025,941	SC 13G/A
Nov 06, 2023	blatt lawrence	5.3%	3,888,253	SC 13D
Nov 02, 2023	deep track capital, lp	9.99%	7,295,967	SC 13G

Recent SEC filings of Aligos Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 16, 2024	PRE 14A	PRE 14A
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Aligos Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Aligos Therapeutics Inc News

Latest updates

Aligos Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-40.1%	694,000	1,158,000	2,154,000	4,294,000	2,583,000	3,537,000	4,106,000	3,693,000	2,571,000	367,000	1,537,000	1,545,000	910,000
Operating Expenses	-19.7%	23,032,000	28,678,000	22,310,000	26,027,000	26,641,000	26,219,000	23,054,000	24,086,000	38,128,000	38,315,000	34,605,000	31,110,000	28,650,000
S&GA Expenses	-100.0%	-	6,421,000	6,443,000	9,246,000	8,506,000	7,119,000	5,263,000	7,576,000	6,452,000	9,717,000	6,473,000	6,556,000	5,781,000
R&D Expenses	-26.5%	16,366,000	22,257,000	15,867,000	16,781,000	18,135,000	19,100,000	17,791,000	16,510,000	31,676,000	28,598,000	28,132,000	24,554,000	22,869,000
EBITDA Margin	-39.9%	-11.71	-8.37	-6.30	-5.48	-5.84	-6.73	-10.19	-15.11	-22.12	-28.71	-	-	-
Income Taxes	180.0%	24,000	-30,000	29,000	757,000	39,000	49,000	-43,000	47,000	53,000	-57,000	126,000	28,000	45,000
Earnings Before Taxes	-24.8%	-34,839,000	-27,922,000	-18,012,000	-18,034,000	-22,916,000	-21,837,000	-18,664,000	-19,877,000	-35,562,000	-37,772,000	-32,998,000	-29,790,000	-27,629,000
EBT Margin	-39.6%	-11.90	-8.53	-6.43	-5.61	-5.98	-6.90	-10.42	-15.45	-22.61	-29.41	-	-	-
Net Income	-25.0%	-34,863,000	-27,892,000	-18,041,000	-18,791,000	-22,955,000	-21,886,000	-18,621,000	-19,924,000	-35,615,000	-37,715,000	-33,124,000	-29,818,000	-27,674,000
Net Income Margin	-39.4%	-12.00	-8.61	-6.50	-5.66	-5.99	-6.91	-10.42	-15.47	-22.64	-29.44	-	-	-
Free Cashflow	-0.4%	-22,753,000	-22,665,000	-20,343,000	-13,623,000	-22,394,000	-16,874,000	-17,140,000	-25,369,000	-20,949,000	-37,816,000	-25,465,000	-23,170,000	-30,103,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-15.6%	128	152	86.00	106	122	147	164	183	210	235	263	212	235	265	92.00	147
Current Assets	-16.3%	118	141	75.00	94.00	109	134	150	168	195	204	249	197	220	250	74.00	120
Cash Equivalents	-82.0%	24.00	136	70.00	91.00	79.00	81.00	86.00	71.00	105	187	240	188	200	221	32.00	70.00
Net PPE	-6.5%	3.00	3.00	4.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	7.00	8.00	8.00	9.00	9.00
Liabilities	14.6%	68.00	59.00	31.00	36.00	37.00	43.00	42.00	46.00	58.00	51.00	46.00	43.00	39.00	45.00	46.00	29.00
Current Liabilities	-21.0%	19.00	24.00	22.00	27.00	28.00	33.00	31.00	32.00	41.00	39.00	35.00	30.00	25.00	30.00	20.00	14.00
Shareholder's Equity	-35.1%	60.00	92.00	55.00	70.00	85.00	104	122	137	153	185	217	169	195	220	-	-
Retained Earnings	-7.2%	-521	-486	-458	-440	-422	-399	-377	-358	-338	-303	-265	-232	-202	-174	-140	-66.20
Additional Paid-In Capital	0.5%	581	578	513	510	506	503	499	496	491	487	483	401	398	395	4.00	1.00
Shares Outstanding	0.8%	76.00	75.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	43.00	39.00	38.00	37.00	38.00	3.00	4.00
Float	-	-	-	-	20.00	-	-	-	35.00	-	-	-	26.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-0.4%	-22,746	-22,658	-20,336	-13,616	-22,387	-16,783	-17,137	-25,035	-20,434	-37,480	-25,368	-23,018	-29,796	-19,684	-16,566	-17,694	-20,319	-	-
Share Based Compensation	2.5%	2,648	2,583	3,209	3,196	3,664	3,416	3,491	4,000	3,786	3,651	3,601	3,449	2,756	1,301	1,016	52.00	606	-	-
Cashflow From Investing	-1266214.3%	-88,642	-7.00	-9.00	25,004	19,993	11,604	32,483	-9,976	-60,404	-16,479	-40.00	9,848	9,693	14,937	26,656	14,931	-23,769	-	-
Cashflow From Financing	-100.0%	-19.00	87,936	-21.00	414	-1.00	121	-19.00	83.00	-21.00	552	77,952	95.00	78.00	193,318	-949	27.00	-48.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALGS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue from collaborations	$ 292	$ 2,583
Revenue from customers	694	140
Operating expenses:
Research and development	16,366	18,135
General and administrative	6,666	8,506
Total operating expenses	23,032	26,641
Loss from operations	(22,046)	(23,918)
Interest and other income (expense), net	(12,793)	1,002
Loss before income tax expense	(34,839)	(22,916)
Income tax expense	(24)	(39)
Net loss	(34,863)	(22,955)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	(69)	98
Other comprehensive income (loss)	(69)	98
Comprehensive loss	$ (34,932)	$ (22,857)
Net loss per share, basic	$ (0.22)	$ (0.53)
Net loss per share, diluted	$ (0.22)	$ (0.53)
Weighted average shares of common stock, basic	156,154,156	42,910,065
Weighted average shares of common stock, diluted	156,154,156	42,910,065

ALGS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 24,151	$ 135,704
Restricted cash	216	70
Short-term investments	88,588
Other current assets	5,109	5,310
Total current assets	118,064	141,084
Operating lease right-of-use assets	6,167	6,559
Property and equipment, net	3,046	3,259
Other assets	625	625
Total assets	127,902	151,527
Current liabilities:
Accounts payable	2,842	2,517
Accrued liabilities	12,043	16,842
Operating lease liabilities, current	3,269	3,229
Finance lease liabilities, current	5	10
Deferred revenue from customers, current	721	1,224
Deferred revenue from collaborations, current		84
Total current liabilities	18,880	23,906
Operating lease liabilities, net of current portion	6,994	7,668
Finance lease liabilities, net of current portion	217	231
Warrant liability	41,969	27,596
Long term liability	46	46
Total liabilities	68,106	59,447
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.
Common stock, $0.0001 par value; 320,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 75,668,521 and 42,922,980 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	7	7
Additional paid-in capital	580,973	578,325
Accumulated deficit	(521,660)	(486,797)
Accumulated other comprehensive income	476	545
Total stockholders’ equity	59,796	92,080
Total liabilities and stockholders’ equity	$ 127,902	$ 151,527

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ÃƒÅ¸ agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

CEO	Dr. Lawrence M. Blatt MBA, Ph.D.
WEBSITE	aligos.com
INDUSTRY	Biotechnology
EMPLOYEES	68

Aligos Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aligos Therapeutics Inc? What does ALGS stand for in stocks?

ALGS is the stock ticker symbol of Aligos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aligos Therapeutics Inc (ALGS)?

As of Thu May 16 2024, market cap of Aligos Therapeutics Inc is 49.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers. The fair value of Aligos Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aligos Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALGS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aligos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALGS is over valued or under valued. Whether Aligos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aligos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALGS.

What is Aligos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ALGS's PE ratio (Price to Earnings) is -0.49 and Price to Sales (PS) ratio is 5.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALGS PE ratio will change depending on the future growth rate expectations of investors.